Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study)

Nicola Gianotti, Laura Galli, Renato Maserati, Laura Sighinolfi, Diego Ripamonti, Loredana Palvarini, Sergio Lo Caputo, Emanuele Focà, Benedetto Maurizio Celesia, Franco Baldelli, Gaetana Sterrantino, Adriano Lazzarin

Research output: Contribution to journalArticle

Abstract

In a multicentre, open-label, clinical trial, 43 patients virologically suppressed while receiving a standard triple antiretroviral therapy were randomized (1:1:1) to switch to monotherapy with darunavir/ritonavir (DRV/r-MT arm), monotherapy with lopinavir/ritonavir (LPV/r-MT arm) or to continue on the ongoing regimen (cART arm). The proportion (95% CI) of patients with virological success (Snapshot analysis) at week 48 was 73% (48%-90%) in the DRV/r-MT arm, 69% (42%-88%) in the LPV/r-MT arm and 87% (61%-98%) in the cART arm. Virological failure was detected in only one patient receiving LPV/r-MT. The LPV/r-MT arm showed a modest worsening in lipid profile.

Original languageEnglish
Pages (from-to)290-294
Number of pages5
JournalNew Microbiologica
Volume39
Issue number4
Publication statusPublished - Oct 2016

    Fingerprint

Keywords

  • Journal Article

Cite this

Gianotti, N., Galli, L., Maserati, R., Sighinolfi, L., Ripamonti, D., Palvarini, L., Caputo, S. L., Focà, E., Celesia, B. M., Baldelli, F., Sterrantino, G., & Lazzarin, A. (2016). Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study). New Microbiologica, 39(4), 290-294.